Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 4,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Blood samples collected Clear all

Conditions: Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: counseling intervention, educational intervention, psychosocial assessment and care; Behavioral · Other · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chevy Chase, Maryland • Hackensack, New Jersey + 1 more

Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis
Interventions: Not listed
Lead sponsor: University of British Columbia; Other
Eligibility: Up to 20 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2025
U.S. locations: 10
States / cities: San Francisco, California • Gainesville, Florida • Chicago, Illinois + 7 more

Conditions: Infections
Interventions: Cefazolin 3gm for Injection USP and Dextrose Injection USP; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Columbus, Georgia • Oklahoma City, Oklahoma

Conditions: Progressive Glioblastoma, Recurrent Glioblastoma
Interventions: Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 325
States / cities: Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more

Conditions: Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
Interventions: Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy, Magnetic Resonance Imaging, Ommaya Reservoir Tap; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: End Stage Renal Disease
Interventions: pravastatin; Drug
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 12 Months to 18 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Huntington Disease
Interventions: computer vision, remote monitoring, blood, urine, wrist bands, mobile-app; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Interventions: Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy; Biological · Drug · Procedure + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 342
States / cities: Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more

Conditions: Multiple Myeloma
Interventions: plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: COVID-19, Acute Respiratory Infection
Interventions: Not listed
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Bevacizumab, Biopsy, Biospecimen Collection, Pegcetacoplan, Pembrolizumab, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Heart Failure, Congestive
Interventions: ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination; Drug · Procedure · Behavioral
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Illumina, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 10
States / cities: Newark, Delaware • Boston, Massachusetts • New Brunswick, New Jersey + 6 more

Conditions: Breast Cancer
Interventions: Blood & Fecal Collection; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Congenital Anomaly, Pediatric Cancer
Interventions: Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Nemtabrutinib, Lisocabtagene Maraleucel; Drug · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Heart Failure
Interventions: Remote Cardiac Rehabilitation (CR); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Individuals
Interventions: Blood Draw; Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pancreatitis
Interventions: blood sampling; Genetic
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 100 Years
Enrollment: 2,980 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer, Early-stage Breast Cancer
Interventions: Prescreening, Screening and Enrollment, Baseline, Interpret BMI, Interpret HbA1c, Interpret lipid panel and assess other risk factors, Assess 10 year risk of cardiovascular event, Recommendations, Follow-Up; Other · Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: mutation analysis, cytology specimen collection procedure, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Ovarian Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteer, Alcohol Consumption
Interventions: Alcohol (Ethanol); Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Denton, Texas • San Antonio, Texas

Search by objective public record fields.

Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions

Pediatric Vasculitis Initiative

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Prophylaxis and Treatment of COVID-19

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer

Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Efficacy and Safety of ICD Remote Monitored Exercise Testing to Improve Heart Failure Outcomes: REMOTE HF-ACTION

Gene Polymorphism Study of Normal Individual Inflammasome Genes

The North American Pancreatitis Study

Cardiometabolic Screening Program

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Phosphatidylethanol and Other Ethanol Consumption Markers